This brand name is authorized in Brazil, Ecuador.
The drug HEMOBLOCK contains one active pharmaceutical ingredient (API):
1
|
UNII
6T84R30KC1 - TRANEXAMIC ACID
|
|
Tranexamic acid is an antifibrinolytic that competitively inhibits the activation of plasminogen to plasmin. Tranexamic acid is a competitive inhibitor of plasminogen activation, and at much higher concentrations, a noncompetitive inhibitor of plasmin, i.e., actions similar to aminocaproic acid. Tranexamic acid is about 10 times more potent in vitro than aminocaproic acid. Tranexamic acid binds more strongly than aminocaproic acid to both the strong and weak receptor sites of the plasminogen molecule in a ratio corresponding to the difference in potency between the compounds. |
|
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC Group | Classification | |
|---|---|---|
| B02AA02 | Tranexamic acid | B Blood and blood forming organs → B02 Antihemorrhagics → B02A Antifibrinolytics → B02AA Amino acids |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| BR | Câmara de Regulação do Mercado de Medicamentos | 531615060078417 |
| EC | Agencia Nacional de Regulación, Control y Vigilancia Sanitaria | 1207-MEE-0815, 28983-08-09, 29103-11-09 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.